Court Upholds Johnson & Johnson’s Patent, Blocking Teva’s Generic Schizophrenia Drug

In a legal win for Johnson & Johnson, Teva Pharmaceuticals USA Inc. has faced a setback in its attempt to challenge the validity of a patent concerning a widely-used schizophrenia drug. A New Jersey federal judge dismissed Teva’s claims, which argued that the formula in question was obvious. This decision effectively halts Teva’s efforts to produce a generic version of the medication, reinforcing the patent’s legitimacy. For further details on the ruling, you can read more about the case here.